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a b s t r a c t 
Background: Hypertonic saline (HS) is commonly prescribed for children with cystic fibrosis (CF) despite
the absence of strong data indicating clinical efficacy in a population with mild lung disease. We hypoth- 
esized that HS treatment would result in a sustained improvement in mucociliary clearance (MCC) in
children with CF who had minimal lung disease, thus providing evidence for a biologically relevant effect
that also may be associated with clinical improvements.
Methods: We performed a randomized, placebo controlled, double blind study of 6% versus 0.12% sodium
chloride, delivered three-times daily with an eFlow nebulizer for 4 weeks. MCC was measured using
gamma scintigraphy at baseline, 2-hours after the first study treatment, and ~12-hours after the final
dose (at day 28). Spirometry, respiratory symptoms (CFQ-R), and safety were also assessed.
Results: Study treatments were generally well tolerated and safe. HS (6% sodium chloride) resulted in
a significant, sustained improvement from baseline in whole lung clearance after 4 weeks of therapy
( p = 0.014), despite absence of a prolonged single-dose effect after the initial dose. This sustained change 
(12 hrs after prior dose) was significantly greater when compared to placebo (0.12% sodium chloride)
treatment ( p = 0.016). Improvements in spirometry with HS did not reach statistical significance but 
correlated with MCC changes.
Conclusions: The observed sustained improvement in MCC with HS suggests that this treatment may yield
health benefits, even in relatively mildly affected children with CF. Highlighting this physiologic finding














o  1. Introduction
The absence of cystic fibrosis transmembrane regulator (CFTR)
protein function results in dehydration of airway secretions in pa-
tients with CF [1] . Over time, CF airway secretions progressively
obstruct airway lumens and serve as the nidus of chronic airway
infection. Strategies that reverse airway service liquid (ASL) dehy-
dration and support mucus transport, therefore, address the pri-∗ Corresponding author at: Professor of Medicine, Marsico Lung Institute, 125 Ma- 
son Farm Rd, CB# 7248, Chapel Hill, NC 27599.
E-mail address: scott_donaldson@med.unc.edu (S.H. Donaldson).







https://doi.org/10.1016/j.jcf.2020.07.009ary pathogenesis of CF lung disease and are expected to improve
linical outcomes [2] . 
The simplest approach to hydrate mucus is the use of inhaled
yperosmolar solutions. Elkins and colleagues tested inhaled 7%
odium chloride given twice daily and demonstrated a large re-
uction in pulmonary exacerbation frequency and improved lung
unction [3] . In separate studies, HS had durable ( > 4 hrs) effects
n mucociliary clearance (MCC) in CF adults after a single dose [4] ;
CC effects lasting > 8–12 h were observed after 2 weeks of re-
eated use [5] . It has been speculated that the prolonged improve-
ent in MCC is responsible for the prevention of CF exacerbations.
Building on these data, recent studies evaluated HS in young
hildren with CF. Large controlled studies evaluating HS in CF in-





















































































































i  uency, but did demonstrate improvement in infant lung function
nd the lung clearance index (LCI), reflecting improved ventilation
nhomogeneity [6, 7] . A subsequent study in CF preschoolers vali-
ated these findings, reporting a moderate improvement in LCI but
o impact on pulmonary exacerbations [8, 9] . While there are mul-
iple reasonable explanations for the apparent lack of effect on ex-
cerbations in CF children, it raises the question whether HS effi-
acy depends upon patient age or disease severity. Further, it raises
he question whether HS causes a sustained MCC improvement in
hese young patients, as is likely required to prevent disease ex-
cerbations. Despite these uncertainties, HS is now prescribed for
5% of patients ≥6 years of age, and 50% of patients between 3
nd 5 years of age [10] . In this study, we tested the hypothesis
hat inhaled HS would have a sustained effect on MCC in CF chil-
ren with mild lung disease, and would translate into improved
linical outcomes. 
. Methods
.1. Study design 
We conducted a randomized, placebo controlled, double-blind
arallel group study to test our hypotheses. Subjects were re-
ruited from the University of North Carolina Pediatric CF Clinic
etween October 2009 and June 2012. Inclusion criteria included:
ge ≥ 5 to 〈 18 years; a confirmed CF diagnosis; and a FEV 1 〉 60%
f predicted. Patients with unstable lung disease, who did not tol-
rate HS, or who were unable/unwilling to withhold prescribed
S for at least 2 weeks before the screening visit were excluded.
he predefined primary outcome was the change in average whole
ung MCC measured over 90 min (AveClr90) between baseline and
 weeks of treatment. Secondary efficacy measures included the
hange in FEV 1 and the CFQ-R respiratory symptom domain score.
xploratory outcomes included single dose MCC effects, and the ef-
ect of study treatments in lung subcompartments (e.g. central and
eripheral lung) and other time domains (e.g. 24 hrs). 
Study treatments consisted of either 6% or 0.12% sodium chlo-
ide (4 ml) administered three times daily via an investigational
Flow nebulizer (Pari Respiratory Equipment, Inc, Midlothian, VA)
or 4 weeks. The active treatment (6% NaCl) and delivery device
ere selected in an effort to balance the desire to maximize NaCl
elivery to the lung against factors that could reduce treatment
olerability (e.g. higher salt concentration, faster aerosol output
ate) or feasibility (e.g. frequency of dosing, treatment time). The
lacebo solution was selected to provide a low osmotic load while
voiding the deleterious effects that may occur after inhalation of
istilled water [11] . A randomization schedule was generated and
aintained by the investigational drug service. 
During a screening visit, eligible subjects were randomized and
eceived a test dose of the assigned study treatment after use of
 bronchodilator (albuterol or levalbuterol; 2 puffs with spacer).
pirometry was performed pre/post bronchodilator and 15 min
fter completing inhalation of the assigned study treatment test
ose. Subjects returned for baseline measures of spirometry and
CC after the screening visit. The first day of the treatment pe-
iod occurred 7–14 days after screening. At this visit the CFQ-
 score and spirometry were obtained prior to study medication
dministration. MCC was measured two hours after study med-
cation to assess the durability of its effect after a single study
reatment dose. Subjects were assessed either via phone or in
linic on day 14 to query for interval adverse events. On day
8, subjects returned to the clinic after holding study medica-
ions overnight. CFQ-R, spirometry and MCC were again performed.
he timing between bronchodilator and MCC was constant at each
isit. This study was reviewed and approved by the institutional hu-
an ethics committee at the University of North Carolina and the
tudy was registered on ClinicalTrials.gov (NCT01031706). All sub-
ects and parents provided signed informed consent and/or assent
o participate in this study. 
.2. Spirometry 
Spirometry was obtained using a KoKo hand-held spirometer
nSpire Health, Inc; Longmont, CO) by trained study staff accord-
ng to ATS/ERS guidelines [12] . Wang pediatric predicted equations
ere used for reference. 
.3. Respiratory symptoms 
Respiratory symptoms were assessed with age and role-
ppropriate versions of the Cystic Fibrosis Questionnaire – Revised
CFQ-R) [13] . Symptom scores ranged from 0 to 100, with higher
alues indicating fewer symptoms. 
.4. Measurement of MCC 
Gamma scintigraphy was performed as previously described
14] at three separate visits to measure MCC at baseline, 2 h af-
er the first dose of study treatment, and 12 h after the final dose
f treatment. Briefly, a transmission image was obtained to outline
ung borders and define regions of interest (ROIs) using a planar
o 57 source. Nebulized Tc 99m -sulfur colloid particles were inhaled
ith a defined breathing pattern: 30 breaths per minute; 1 s inspi-
atory time; and 30 0–50 0 ml/ sec inspiratory flow rate according
o the subject’s height; until a deposited dose of 20–40 uCi was
chieved (typically, 2–3 min). Serial 2-minute gamma scintigraphy
mages tracked particle retention. During the first 64 min, subjects
ere asked to refrain from coughing to allow assessment of cilia-
riven clearance. Subjects then performed 20 voluntary coughs
hrough a peak-flow meter every ten minutes to assess cough-
ssisted clearance for an additional 30 min. Subjects returned 24 h
ater to assess particle retention at this later time point. All images
ere corrected for background radiation and radioactive decay of
c 99m . 
.5. MCC image analyses 
The initial pattern of particle deposition in the whole right
ung was characterized by calculating the central:peripheral ratio
f Tc99m activity, normalized to the central:peripheral Co 57 activ-
ty ratio (transmission scan) to adjust for regional differences in
ung thickness. 
Percent particle clearance (100 -% retention) from the whole
ight lung and subregions (central and peripheral ROIs) were plot-
ed over time. Clearance versus time curves were numerically rep-
esented by calculating average clearance rates using values at 10-
inute intervals in each ROI. Cummulative clearance through 24-
rs was measured with a static image at that time point. 
.6. Statistical analyses 
A between treatment comparison of the change in AveClr90 in
he whole right lung region, via an independent Student’s t -test,
erved as the primary study outcome. A paired t -test comparing
veClr90 at baseline and at day 28 was performed in each group
o assess within treatment changes in MCC. Linear regressions on
he change of AveClr90 explored the impact of potential covariates
i.e. C/P ratio, baseline FEV 1 , gender). Comparisons of the change
n AveClr90 between baseline and 2 hrs after the first dose of each
Table 1
Subject Demographics.
Active (6% NaCl) ( n = 14) Placebo (0.12% NaCl) ( n = 9) All subjects ( n = 23) 
Female,% 8 (57%) 4 (44%) 12 (52%)
Age, years (SD) 11.9 (3.3) 9.8 (3.6) 11.1 (3.5)
Post-BD FVC,% predicted (SD) 101.4 (12.3) 100.0 (10.9) 100.8 (11.5)
Post-BD FEV 1 ,% predicted (SD) 97.0 (12.6) 93.2 (13.4) 95.5 (12.8)
Post-BD FEF 25–75 ,% predicted (SD) 91.1 (24.9) 86.2 (37.8) 89.7 (27.9)
Inhaled antibiotics (%) 2 (14%) 1 (11%) 3 (13%)
Chronic HS (%) 1 (7%) 3 (33%) 4 (17%)
Dornase Alfa (%) 3 (36%) 4 (44%) 9 (39%)
Pancreatic Sufficient (%) 0 (0%) 1 (11%) 1 (4%)
Abbreviations: SD – Standard Deviation, BD – bronchodilator, FVC – forced vital capacity, FEV 1 – Forced Expiratory Volume
in 1 s, FEF 25–75 - Forced expiratory flow 25–75%. No subjects used CFTR modulators during this study.
Table 2
Mucociliary Clearance and Deposition Data.
Baseline First Dose 4 weeks Mean 4 week change
Placebo
Whole Lung
AveClr60 (%) 11.8 ± 11.2 10.2 ± 8.7 10.3 ± 8.3 −3.1 ± 5.5 (CI: −7.8 – 1.5)
AveClr90 (%) 13.9 ± 10.7 12.6 ± 9.8 13.3 ± 9.3 −2.3 ± 5.2 (CI: −6.7 – 2.0)
24-hr Clearance (%) 33.4 ± 6.8 35.4 ± 5.9 34.8 ± 14.1 0.6 ± 11.9 (CI: −9.4 – 10.6)
C/P ratio 1.83 ± 0.20 2.09 ± 0.14 ∗ 1.92 ± 0.25 0.12 ± 0.23 (CI: −0.07 – 0.30)
Central Lung
AveClr90 (%) 22.0 ± 15.4 17.8 ± 15.7 21.0 ± 14.5 −3.8 ± 9.3 (CI: −11.6 – 4.0)
Peripheral Lung
AveClr90 (%) 8.5 ± 10.4 8.9 ± 5.6 7.8 ± 5.8 −1.7 ± 8.9 (CI: −9.2 – 5.7)
Active Treatment
Whole Lung
AveClr60 (%) 7.5 ± 5.2 8.3 ± 5.2 9.9 ± 6.2 1.6 ± 4.1 (CI: −1.2 – 4.3) ∗∗
AveClr90 (%) 9.1 ± 5.1 10.5 ± 5.9 12.6 ± 6.4 ∗ 2.8 ± 3.2 (CI: 0.6 – 4.9) ∗∗
24-hr Clearance (%) 24.0 ± 8.8 38.6 ± 12.8 ∗ 25.0 ± 8.0 1.6 ± 6.1 (CI: −2.3 – 5.5) 
C/P ratio 1.67 ± 0.32 1.87 ± 0.35 ∗ 1.66 ± 0.26 −0.01 ± 0.26 (CI: −0.18 – 0.15)
Central Lung
AveClr90 (%) 16.2 ± 13.6 16.8 ± 8.7 20.8 ± 9.2 2.6 ± 9.0 (CI: −3.5 – 8.6) 
Peripheral Lung
AveClr90 (%) 6.1 ± 4.4 6.5 ± 4.8 7.3 ± 4.9 1.1 ± 4.7 (CI: −2.1 – 4.3) 
Clearance and deposition values at each time point, and calculated mean differences between baseline and 4
week visit.
∗ Significant difference ( p < 0.05) from baseline via paired T-test.




































t  study treatment were performed to characterize the acute pharma-
codynamic effect of HS with Student t-tests and linear models. The
between and within group changes in CFQ-R scores, spirometry
values, and secondary MCC outcomes were similarly analyzed. Cor-
relations between endpoints of interest were calculated with the
Pearson correlation. All results are reported as mean ± standard
deviation. For calculated differences, mean and 95% confidence in-
tervals were calculated. 
A proposed sample size of 24 subjects was estimated to pro-
vide approximately 80% power at a two-sided significance level of
0.05 to detect a treatment difference of 6.6% (absolute change in
MCC). A treatment difference of this magnitude approximated the
sustained effect observed with HS treatment in older CF patients
with more severe lung disease. 
3. Results
3.1. Subjects 
Twenty four subjects were screened for the study, with one
screen failure. Twenty-three subjects were enrolled and underwent
randomization. Fourteen subjects were randomized to receive ac-
tive treatment with 6% NaCl, and 9 to the placebo solution (0.12%
NaCl). Baseline subject characteristics are shown in Table 1 . On av-rage, subjects (mean age 11.1 yrs) used relatively few chronic ther-
pies and had normal FEV 1 and FEF 25–75 values, signifying mild
ung disease. Expectorated sputum samples could only be collected
rom 3 of 23 subjects either before or after the treatment period,
eflecting their mild disease. 
.2. Safety 
No subject met any objective withdrawal criteria following the
est dose. Disposition of subjects is indicated in Fig. 1 . Frequency of
dverse events were similar between groups (Supplement Table 1 ).
The acute effect of study treatments on spirometry was as-
essed 15 min after inhalation. At this early time point, a
6.4 ± 6.4% change in FEV 1 was observed in the HS group, ver-
us a −1.3 ± 4.5% change in the placebo group ( p = 0.04). No sub-
ect exceeded the pre-defined 20% relative drop in FEV 1 that would
ave triggered additional spirometric testing. None experienced
xygen desaturation, or had clinically apparent bronchospasm.
3.3. Mucociliary clearance 
Mucociliary clearance was measured at baseline, 2 h after the
rst dose, and approximately 12 h after the final dose of study
reatment. Results are shown in Table 2 . Neither treatment was as-

























ociated with a change in AveClr90 measured 2 h after the first
ose, suggesting that any acute effect on airway clearance was
hort-lived. However, the “first dose” of HS, but not placebo so-
ution, was associated with a significant increase in 24-hr whole
ung clearance. Because subjects initiated thrice daily treatment
ith study medications before returning for this 24-hr retention
mage, these additional treatments likely provided repeated, tran-
ient improvements in clearance that were detected at the 24-hr
imepoint. Importantly, a modest increase in radioaerosol deposi-
ion index (i.e. C/P ratio) between baseline and this “first dose”
tudy was observed in both treatment groups, which if anything
ould bias the result toward faster post-treatment clearance rates.t  he lack of improvement in AveClr90 in either arm, therefore, can-
ot be explained by a change in radioaerosol deposition. 
In contrast, whole lung AveClr90 measured after 4 weeks of
reatment was significantly faster than baseline in the HS group
 p = 0.014), whereas no change from baseline was observed in
he placebo group ( Table 2 , Fig. 2 ). Comparison of the change from
aseline between groups ( p = 0.016) was also significant, favoring
S ( Table 2 , Fig. 2 ). Using mixed linear models, we were unable
o identify any significant clinical features (e.g. age, gender, base-
ine FEV 1 ) or MCC covariates (C/P ratio) that influenced treatment
esponses. 
MCC responses in the central and peripheral lung regions of in-
erest revealed similar trends toward improvements in MCC after
Fig. 2. Spaghetti plots (left) showing individual AveClr90 values at baseline and after 4 weeks of treatment by treatment group. In right panel, scatter plots with mean and
95% CI demonstrate the mean change in AveClr90 between baseline and after 4 weeks of treatment in placebo and HS groups. Unpaired Student’s t -test revealed significant































Fig. 3. Correlation between change in MCC (AveClr90) and FEV 1 % predicted after 4




























a  HS but the placebo treatment did not reach statistical significance
( Table 2 ). 
3.4. CFQ-R respiratory domain 
The treatment effect of HS versus placebo on the CFQ-R res-
piratory symptom domain between baseline and at the end of
the assigned treatment was + 7.3 ± 5.1. Although greater than
the accepted minimum clinically important difference (MCID) of
4 for this instrument, it did not reach statistical significance
( p = 0.17). Similarly, a non-significant within group improvement
in the CFQ-R respiratory domain score was observed in the HS
group ( + 5.8 ± 12.6; p = 0.18), but not in the placebo group
( −1.6 ± 9.8).
3.5. Lung function 
The treatment difference in FEV 1 % predicted (absolute change)
between the active and placebo groups following 4 weeks of treat-
ment was 1.9 ± 3.3% ( p = NS). The within group improvement in
FEV 1 % predicted after HS (3.2 ± 7.0%) was also not significant. 
3.6. Correlation between endpoints 
Correlations between various endpoints were calculated to ex-
plore the role that MCC measurements might play in this popula-
tion. At baseline, no relationships between baseline MCC rates and
subject age, gender, or baseline FEV 1 were noted. Correlation be-
tween AveClr90 values at baseline and after 4 weeks of treatment
were highly significant, indicating that repeated MCC measure-
ments in individual subjects are reliable (R 2 = 0.75, p = 0.0 0 05 for
active treatment, R 2 = 0.74, p = 0.007 for placebo). Interestingly,
the correlation between changes in AveClr90 and FEV 1 revealed a
highly significant relationship in subjects who were randomized to
HS (R 2 = 0.67, p = 0.002; Fig 3 ), suggesting that sustained improve-
ment in MCC might predict improvements in lung function, even
in this mildly affected population. No other factors correlated with
the observed change in FEV 1 , and no relationship between changes
in MCC and respiratory symptoms were observed. 
4. Discussion
The demonstration of treatment efficacy in mildly affected CF
is a growing challenge. This is particularly problematic in pedi-
atric populations where the median FEV 1 currently remains > 90%
of predicted until early adolescence [10] , and where other outcomeeasures may not be well suited to younger patients. The identi-
cation of endpoints that are physiologically relevant, feasible in
oung populations, sensitive, repeatable, and not limited by ceiling
ffects are necessary to guide drug development and inform treat-
ent decisions in young CF populations. 
The use of HS provides a clear example of this dilemma.
hereas trials of HS in older CF populations provided fairly clear
ignals of clinical efficacy [3, 5] , similar large studies in toddlers
nd preschoolers were less definitive. Although LCI measurements
emonstrated clear HS treatment effects [6, 8] , the lack of improve-
ent in exacerbation frequency raises uncertainty over the clini-
al benefit of HS in this population. In parallel, marked differences
n MCC responses to HS in healthy [15] and CF adult populations
4] also raise concerns that a mildly affected CF patient might ben-
fit less from HS than a more severely affected CF adult. Indeed,
 single dose HS study by Laube et al. failed to show overall im-
rovement in MCC in CF children [16] . 
In this trial, we observed a significant, sustained improvement
n MCC after 4 weeks of dosing. The average relative improvement
n MCC over baseline (~33%) was nearly identical to that reported
n our earlier study of HS in older CF subjects [5] , suggesting that a
imilar, sustained physiologic effect was achieved despite the dif-
erences in disease severity in these studies. In contrast, we did
ot observe a prolonged acute effect on MCC (measured at 2 hrs
ost-dose) after a single HS dose in these CF children, whereas
n CF adults this effect appeared to last > 4 h [4] . Together these
ata suggest that repeated treatment with a relatively short-acting



































































































epetitive dosing. We further speculate that the more prolonged
harmacodynamic effect of a single HS dose in CF adults might re-
ate to their higher mucus burden and its ability to prolong ASL
olume responses to HS, as previously shown by in vitro studies
17] .
We view these study results as complimentary to prior stud-
es of HS in children where physiologic (LCI) improvements were
emonstrated. Together, they increase our confidence that the
emonstrated improvements in airways obstruction and mucus
learance will lead to clinical benefits, despite the challenges
f demonstrating this directly in young, mildly affected CF pa-
ients. Although we view the mechanisms of dornase alfa and
S as being quite distinct, the emergence of CFTR modulators
akes the future role of HS in treatment regimens for CF chil-
ren uncertain. We have demonstrated that highly effective CFTR
odulators markedly improve MCC, likely through similar mech-
nisms as HS (i.e. restoration of mucus properties that facili-
ate clearance). Until highly effective modulators are available for
ll children, HS appears to be a useful part of the maintenance
egimen. 
The role that MCC imaging studies might play in drug develop-
ent in mildly affected CF children is highlighted by two factors.
irst, we showed a clear improvement in MCC in a small group
here ceiling effects on FEV 1 and CFQ-R likely played a role in the
ailure to observe a treatment difference. Second, the strong corre-
ation between changes in MCC and lung function strengthens the
linical meaningfulness of the MCC endpoint. Of note, similar cor-
elations between MCC and lung function changes were also seen
n studies of ivacaftor in CF patients with the G551D-CFTR muta-
ion [18] . MCC may, therefore, be well suited to small trials where
EV 1 ceiling effects and variability may be limiting. It is also in-
riguing to consider use of MCC measurements as a way of as-
essing whether discontinuation or addition of a standard therapy
uch as HS might be appropriate in the context of CFTR modulator
se. 
This study has several limitations. First, although protection
gainst pulmonary exacerbations was the dominant clinical bene-
t in older CF populations, we don’t know whether improvements
n MCC will predict this outcome. Uncertainties in how to define
 CF exacerbation in young populations further complicate this
ilemma. If we knew that improved MCC actually does predict
rotection against pulmonary exacerbations, use of this endpoint
ould help to circumvent this issue of exacerbation definitions in
he young, mildly affected populations. 
Another limitation of our study is the use of a non-standard
S formulation (6% NaCl), treatment frequency and delivery de-
ice. This decreases our ability to extrapolate our results to those
hat might be achieved with more typical clinical regimens (i.e. 7%
aCl, twice daily via jet nebulizer). The desire to optimally test the
ypothesis that inhaled osmotic agents will benefit mild CF lung
isease, balanced against feasibility and tolerability concerns, led
o the selected study design. Taste masking of study solutions was
lso not attempted in this study, increasing the risk that subjects
ight have been aware of their treatment assignment. However,
nly 3 of 23 subjects had used HS at the time of enrollment, re-
ucing this risk. 
. Conclusions
HS is frequently prescribed to young CF patients despite a rel-
tive paucity of data supporting its clinical efficacy. In this study,
S was well tolerated and safe. We demonstrated a sustained im-
rovement in a biologically relevant physiologic process (i.e. MCC),
nd this change correlated with those in FEV 1 . Despite the acute
ffects of HS on MCC being short-lived ( < 2 hrs), repeated dosing
ielded sustained improvements ( > 12 hrs). This observation sug-ests that potent, but short-acting, therapeutics designed to im-
rove MCC might still achieve efficacy with repeated use. In to-
al, observations from this study could influence the pre-clinical
oals of CF drug development (i.e. required pharmacodynamic pro-
le) and how they are tested in early phase clinical trials. Future
ork is needed to define the relationship between MCC responses
nd the risk of pulmonary exacerbations, as well as studies to test
he utility of osmotic hydrators across various CF populations after
he initiation of highly active CFTR modulators. 
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